Can pioglitazone be potentially useful therapeutically in treating patients with covid-19?
Identifieur interne : 000773 ( Pmc/Curation ); précédent : 000772; suivant : 000774Can pioglitazone be potentially useful therapeutically in treating patients with covid-19?
Auteurs : Elena Carboni [Italie] ; Anna Rosa Carta [Italie] ; Ezio Carboni [Italie]Source :
- Medical Hypotheses [ 0306-9877 ] ; 2020.
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic disease (COVID-19) that has spread globally causing more than 30,000 deaths. Despite the immense and ongoing global effort, no efficacious drugs to fight this plague have been identified and patients admitted to the intensive care units (ICU), for respiratory distress, are managed mostly by means of supportive care based on oxygen maintenance. Several authors have reported that the prevalence of hypertension, diabetes, cardiovascular and cerebrovascular diseases comorbidities were indeed frequent among patients with COVID-19, which suggests that these conditions are likely to aggravate and complicate the prognosis. What the aforementioned diseases have in common is a latent chronic inflammatory state that may be associated with the alteration of laboratory parameters that are typical of the metabolic syndrome and insulin resistance. In severe COVID-19 patients laboratory markers of inflammation such as C-reactive protein, IL-6, D-dimer, serum ferritin and lactate dehydrogenase are elevated in many patients; assessed since the 4th-6th day of illness onset, such increases seem to be predictive of an adverse prognosis. Our hypothesis is that drugs belonging to the family of thiazolidinediones (TZD) such as pioglitazone or rosiglitazone, approved for treating the condition of insulin resistance and the accompanying inflammation, could ameliorate the prognosis of those COVID-19 patients with diabetes, hypertension and cardiovascular disorders comorbidities. TZD are PPARγ agonists that act on nuclear receptors, thereby triggering certain transcription factors. TZD were widely used for type-2 diabetes in the first decade of this century and although concerns have been raised for possible side effects associated with long-term treatment, their use has been recently revaluated for their anti-inflammatory properties in numerous medical conditions.
Url:
DOI: 10.1016/j.mehy.2020.109776
PubMed: 32344313
PubMed Central: 7175844
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000773
Links to Exploration step
PMC:7175844Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Can pioglitazone be potentially useful therapeutically in treating patients with covid-19?</title>
<author><name sortKey="Carboni, Elena" sort="Carboni, Elena" uniqKey="Carboni E" first="Elena" last="Carboni">Elena Carboni</name>
<affiliation wicri:level="1"><nlm:aff id="af015">Ezio Carboni, Dept. of Bimedical Sciences, Cittadella Universitaria di Monserrato, Blocco A, S.P. Monserrato Sestu km 0,7, 09042 Monserrato. CA, Italy</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Ezio Carboni, Dept. of Bimedical Sciences, Cittadella Universitaria di Monserrato, Blocco A, S.P. Monserrato Sestu km 0,7, 09042 Monserrato. CA</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Carta, Anna Rosa" sort="Carta, Anna Rosa" uniqKey="Carta A" first="Anna Rosa" last="Carta">Anna Rosa Carta</name>
<affiliation wicri:level="1"><nlm:aff id="af005">Department of Biomedical Sciences, University of Cagliari, Italy</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Biomedical Sciences, University of Cagliari</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Carboni, Ezio" sort="Carboni, Ezio" uniqKey="Carboni E" first="Ezio" last="Carboni">Ezio Carboni</name>
<affiliation wicri:level="1"><nlm:aff id="af005">Department of Biomedical Sciences, University of Cagliari, Italy</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Biomedical Sciences, University of Cagliari</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="af010">Department of Paediatrics, Magna Graecia University of Catanzaro, Italy</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Paediatrics, Magna Graecia University of Catanzaro</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">32344313</idno>
<idno type="pmc">7175844</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175844</idno>
<idno type="RBID">PMC:7175844</idno>
<idno type="doi">10.1016/j.mehy.2020.109776</idno>
<date when="2020">2020</date>
<idno type="wicri:Area/Pmc/Corpus">000773</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000773</idno>
<idno type="wicri:Area/Pmc/Curation">000773</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000773</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Can pioglitazone be potentially useful therapeutically in treating patients with covid-19?</title>
<author><name sortKey="Carboni, Elena" sort="Carboni, Elena" uniqKey="Carboni E" first="Elena" last="Carboni">Elena Carboni</name>
<affiliation wicri:level="1"><nlm:aff id="af015">Ezio Carboni, Dept. of Bimedical Sciences, Cittadella Universitaria di Monserrato, Blocco A, S.P. Monserrato Sestu km 0,7, 09042 Monserrato. CA, Italy</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Ezio Carboni, Dept. of Bimedical Sciences, Cittadella Universitaria di Monserrato, Blocco A, S.P. Monserrato Sestu km 0,7, 09042 Monserrato. CA</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Carta, Anna Rosa" sort="Carta, Anna Rosa" uniqKey="Carta A" first="Anna Rosa" last="Carta">Anna Rosa Carta</name>
<affiliation wicri:level="1"><nlm:aff id="af005">Department of Biomedical Sciences, University of Cagliari, Italy</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Biomedical Sciences, University of Cagliari</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Carboni, Ezio" sort="Carboni, Ezio" uniqKey="Carboni E" first="Ezio" last="Carboni">Ezio Carboni</name>
<affiliation wicri:level="1"><nlm:aff id="af005">Department of Biomedical Sciences, University of Cagliari, Italy</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Biomedical Sciences, University of Cagliari</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="af010">Department of Paediatrics, Magna Graecia University of Catanzaro, Italy</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Paediatrics, Magna Graecia University of Catanzaro</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Medical Hypotheses</title>
<idno type="ISSN">0306-9877</idno>
<idno type="eISSN">1532-2777</idno>
<imprint><date when="2020">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic disease (COVID-19) that has spread globally causing more than 30,000 deaths. Despite the immense and ongoing global effort, no efficacious drugs to fight this plague have been identified and patients admitted to the intensive care units (ICU), for respiratory distress, are managed mostly by means of supportive care based on oxygen maintenance. Several authors have reported that the prevalence of hypertension, diabetes, cardiovascular and cerebrovascular diseases comorbidities were indeed frequent among patients with COVID-19, which suggests that these conditions are likely to aggravate and complicate the prognosis. What the aforementioned diseases have in common is a latent chronic inflammatory state that may be associated with the alteration of laboratory parameters that are typical of the metabolic syndrome and insulin resistance. In severe COVID-19 patients laboratory markers of inflammation such as C-reactive protein, IL-6, D-dimer, serum ferritin and lactate dehydrogenase are elevated in many patients; assessed since the 4th-6th day of illness onset, such increases seem to be predictive of an adverse prognosis. Our hypothesis is that drugs belonging to the family of thiazolidinediones (TZD) such as pioglitazone or rosiglitazone, approved for treating the condition of insulin resistance and the accompanying inflammation, could ameliorate the prognosis of those COVID-19 patients with diabetes, hypertension and cardiovascular disorders comorbidities. TZD are PPARγ agonists that act on nuclear receptors, thereby triggering certain transcription factors. TZD were widely used for type-2 diabetes in the first decade of this century and although concerns have been raised for possible side effects associated with long-term treatment, their use has been recently revaluated for their anti-inflammatory properties in numerous medical conditions.</p>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Guo, Y R" uniqKey="Guo Y">Y.R. Guo</name>
</author>
<author><name sortKey="Cao, Q D" uniqKey="Cao Q">Q.D. Cao</name>
</author>
<author><name sortKey="Hong, Z S" uniqKey="Hong Z">Z.S. Hong</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Li, B" uniqKey="Li B">B. Li</name>
</author>
<author><name sortKey="Yang, J" uniqKey="Yang J">J. Yang</name>
</author>
<author><name sortKey="Zhao, F" uniqKey="Zhao F">F. Zhao</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Zhang, J J" uniqKey="Zhang J">J.J. Zhang</name>
</author>
<author><name sortKey="Dong, X" uniqKey="Dong X">X. Dong</name>
</author>
<author><name sortKey="Cao, Y Y" uniqKey="Cao Y">Y.Y. Cao</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Peng, Y D" uniqKey="Peng Y">Y.D. Peng</name>
</author>
<author><name sortKey="Meng, K" uniqKey="Meng K">K. Meng</name>
</author>
<author><name sortKey="Guan, H Q" uniqKey="Guan H">H.Q. Guan</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Li, L Q" uniqKey="Li L">L.Q. Li</name>
</author>
<author><name sortKey="Huang, T" uniqKey="Huang T">T. Huang</name>
</author>
<author><name sortKey="Wang, Y Q" uniqKey="Wang Y">Y.Q. Wang</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Kanda, Y" uniqKey="Kanda Y">Y. Kanda</name>
</author>
<author><name sortKey="Shimoda, M" uniqKey="Shimoda M">M. Shimoda</name>
</author>
<author><name sortKey="Hamamoto, S" uniqKey="Hamamoto S">S. Hamamoto</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Liu, W" uniqKey="Liu W">W. Liu</name>
</author>
<author><name sortKey="Tao, Z W" uniqKey="Tao Z">Z.W. Tao</name>
</author>
<author><name sortKey="Lei, W" uniqKey="Lei W">W. Lei</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Liu, Y" uniqKey="Liu Y">Y. Liu</name>
</author>
<author><name sortKey="Yang, Y" uniqKey="Yang Y">Y. Yang</name>
</author>
<author><name sortKey="Zhang, C" uniqKey="Zhang C">C. Zhang</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Huang, C" uniqKey="Huang C">C. Huang</name>
</author>
<author><name sortKey="Wang, Y" uniqKey="Wang Y">Y. Wang</name>
</author>
<author><name sortKey="Li, X" uniqKey="Li X">X. Li</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Gao, Y" uniqKey="Gao Y">Y. Gao</name>
</author>
<author><name sortKey="Li, T" uniqKey="Li T">T. Li</name>
</author>
<author><name sortKey="Han, M" uniqKey="Han M">M. Han</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Fu, Y" uniqKey="Fu Y">Y. Fu</name>
</author>
<author><name sortKey="Cheng, Y" uniqKey="Cheng Y">Y. Cheng</name>
</author>
<author><name sortKey="Wu, Y" uniqKey="Wu Y">Y. Wu</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Chen, L" uniqKey="Chen L">L. Chen</name>
</author>
<author><name sortKey="Liu, H G" uniqKey="Liu H">H.G. Liu</name>
</author>
<author><name sortKey="Liu, W" uniqKey="Liu W">W. Liu</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Yu, F" uniqKey="Yu F">F. Yu</name>
</author>
<author><name sortKey="Du, L" uniqKey="Du L">L. Du</name>
</author>
<author><name sortKey="Ojcius, D M" uniqKey="Ojcius D">D.M. Ojcius</name>
</author>
<author><name sortKey="Pan, C" uniqKey="Pan C">C. Pan</name>
</author>
<author><name sortKey="Jiang, S" uniqKey="Jiang S">S. Jiang</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Gu, J" uniqKey="Gu J">J. Gu</name>
</author>
<author><name sortKey="Gong, E" uniqKey="Gong E">E. Gong</name>
</author>
<author><name sortKey="Zhang, B" uniqKey="Zhang B">B. Zhang</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Li, Y C" uniqKey="Li Y">Y.C. Li</name>
</author>
<author><name sortKey="Bai, W Z" uniqKey="Bai W">W.Z. Bai</name>
</author>
<author><name sortKey="Hashikawa, T" uniqKey="Hashikawa T">T. Hashikawa</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Chen, T" uniqKey="Chen T">T. Chen</name>
</author>
<author><name sortKey="Wu, D" uniqKey="Wu D">D. Wu</name>
</author>
<author><name sortKey="Chen, H" uniqKey="Chen H">H. Chen</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Mori, I" uniqKey="Mori I">I. Mori</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Netland, J" uniqKey="Netland J">J. Netland</name>
</author>
<author><name sortKey="Meyerholz, D K" uniqKey="Meyerholz D">D.K. Meyerholz</name>
</author>
<author><name sortKey="Moore, S" uniqKey="Moore S">S. Moore</name>
</author>
<author><name sortKey="Cassell, M" uniqKey="Cassell M">M. Cassell</name>
</author>
<author><name sortKey="Perlman, S" uniqKey="Perlman S">S. Perlman</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Bloomgarden, Z T" uniqKey="Bloomgarden Z">Z.T. Bloomgarden</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Lebovitz, H E" uniqKey="Lebovitz H">H.E. Lebovitz</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Esser, N" uniqKey="Esser N">N. Esser</name>
</author>
<author><name sortKey="Legrand Poels, S" uniqKey="Legrand Poels S">S. Legrand-Poels</name>
</author>
<author><name sortKey="Piette, J" uniqKey="Piette J">J. Piette</name>
</author>
<author><name sortKey="Scheen, A J" uniqKey="Scheen A">A.J. Scheen</name>
</author>
<author><name sortKey="Paquot, N" uniqKey="Paquot N">N. Paquot</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Laakso, M" uniqKey="Laakso M">M. Laakso</name>
</author>
<author><name sortKey="Kuusisto, J" uniqKey="Kuusisto J">J. Kuusisto</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Liu, C" uniqKey="Liu C">C. Liu</name>
</author>
<author><name sortKey="Feng, X" uniqKey="Feng X">X. Feng</name>
</author>
<author><name sortKey="Li, Q" uniqKey="Li Q">Q. Li</name>
</author>
<author><name sortKey="Wang, Y" uniqKey="Wang Y">Y. Wang</name>
</author>
<author><name sortKey="Li, Q" uniqKey="Li Q">Q. Li</name>
</author>
<author><name sortKey="Hua, M" uniqKey="Hua M">M. Hua</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="King, G L" uniqKey="King G">G.L. King</name>
</author>
<author><name sortKey="Park, K" uniqKey="Park K">K. Park</name>
</author>
<author><name sortKey="Li, Q" uniqKey="Li Q">Q. Li</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Pfutzner, A" uniqKey="Pfutzner A">A. Pfützner</name>
</author>
<author><name sortKey="Schondorf, T" uniqKey="Schondorf T">T. Schöndorf</name>
</author>
<author><name sortKey="Hanefeld, M" uniqKey="Hanefeld M">M. Hanefeld</name>
</author>
<author><name sortKey="Forst, T" uniqKey="Forst T">T. Forst</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Xie, X" uniqKey="Xie X">X. Xie</name>
</author>
<author><name sortKey="Sinha, S" uniqKey="Sinha S">S. Sinha</name>
</author>
<author><name sortKey="Yi, Z" uniqKey="Yi Z">Z. Yi</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Zhang, W Y" uniqKey="Zhang W">W.Y. Zhang</name>
</author>
<author><name sortKey="Schwartz, E A" uniqKey="Schwartz E">E.A. Schwartz</name>
</author>
<author><name sortKey="Permana, P A" uniqKey="Permana P">P.A. Permana</name>
</author>
<author><name sortKey="Reaven, P D" uniqKey="Reaven P">P.D. Reaven</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Qiu, D" uniqKey="Qiu D">D. Qiu</name>
</author>
<author><name sortKey="Li, X N" uniqKey="Li X">X.N. Li</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Sakamoto, A" uniqKey="Sakamoto A">A. Sakamoto</name>
</author>
<author><name sortKey="Hongo, M" uniqKey="Hongo M">M. Hongo</name>
</author>
<author><name sortKey="Saito, K" uniqKey="Saito K">K. Saito</name>
</author>
<author><name sortKey="Nagai, R" uniqKey="Nagai R">R. Nagai</name>
</author>
<author><name sortKey="Ishizaka, N" uniqKey="Ishizaka N">N. Ishizaka</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Kutsukake, M" uniqKey="Kutsukake M">M. Kutsukake</name>
</author>
<author><name sortKey="Matsutani, T" uniqKey="Matsutani T">T. Matsutani</name>
</author>
<author><name sortKey="Tamura, K" uniqKey="Tamura K">K. Tamura</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Aoki, Y" uniqKey="Aoki Y">Y. Aoki</name>
</author>
<author><name sortKey="Maeno, T" uniqKey="Maeno T">T. Maeno</name>
</author>
<author><name sortKey="Aoyagi, K" uniqKey="Aoyagi K">K. Aoyagi</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Barbarin, V" uniqKey="Barbarin V">V. Barbarin</name>
</author>
<author><name sortKey="Nihoul, A" uniqKey="Nihoul A">A. Nihoul</name>
</author>
<author><name sortKey="Misson, P" uniqKey="Misson P">P. Misson</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Colle, R" uniqKey="Colle R">R. Colle</name>
</author>
<author><name sortKey="De Larminat, D" uniqKey="De Larminat D">D. de Larminat</name>
</author>
<author><name sortKey="Rotenberg, S" uniqKey="Rotenberg S">S. Rotenberg</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Galimberti, D" uniqKey="Galimberti D">D. Galimberti</name>
</author>
<author><name sortKey="Scarpini, E" uniqKey="Scarpini E">E. Scarpini</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Carta, A R" uniqKey="Carta A">A.R. Carta</name>
</author>
<author><name sortKey="Pisanu, A" uniqKey="Pisanu A">A. Pisanu</name>
</author>
<author><name sortKey="Carboni, E" uniqKey="Carboni E">E. Carboni</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Carta, A R" uniqKey="Carta A">A.R. Carta</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Simon, D K" uniqKey="Simon D">D.K. Simon</name>
</author>
<author><name sortKey="Simuni, T" uniqKey="Simuni T">T. Simuni</name>
</author>
<author><name sortKey="Elm, J N I N D S N E T P D" uniqKey="Elm J">J.N.I.N.D.S.N.E.T.-P.D. Elm</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Omeragic, A" uniqKey="Omeragic A">A. Omeragic</name>
</author>
<author><name sortKey="Hoque, M T" uniqKey="Hoque M">M.T. Hoque</name>
</author>
<author><name sortKey="Choi, U Y" uniqKey="Choi U">U.Y. Choi</name>
</author>
<author><name sortKey="Bendayan, R" uniqKey="Bendayan R">R. Bendayan</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Patel, S P" uniqKey="Patel S">S.P. Patel</name>
</author>
<author><name sortKey="Cox, D H" uniqKey="Cox D">D.H. Cox</name>
</author>
<author><name sortKey="Gollihue, J L" uniqKey="Gollihue J">J.L. Gollihue</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Shafaroodi, H" uniqKey="Shafaroodi H">H. Shafaroodi</name>
</author>
<author><name sortKey="Moezi, L" uniqKey="Moezi L">L. Moezi</name>
</author>
<author><name sortKey="Ghorbani, H" uniqKey="Ghorbani H">H. Ghorbani</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Agarwal, R" uniqKey="Agarwal R">R. Agarwal</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Sharma, R" uniqKey="Sharma R">R. Sharma</name>
</author>
<author><name sortKey="Kaundal, R K" uniqKey="Kaundal R">R.K. Kaundal</name>
</author>
<author><name sortKey="Sharma, S S" uniqKey="Sharma S">S.S. Sharma</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Forst, T" uniqKey="Forst T">T. Forst</name>
</author>
<author><name sortKey="Wilhelm, B" uniqKey="Wilhelm B">B. Wilhelm</name>
</author>
<author><name sortKey="Pfutzner, A" uniqKey="Pfutzner A">A. Pfützner</name>
</author>
</analytic>
</biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Med Hypotheses</journal-id>
<journal-id journal-id-type="iso-abbrev">Med. Hypotheses</journal-id>
<journal-title-group><journal-title>Medical Hypotheses</journal-title>
</journal-title-group>
<issn pub-type="ppub">0306-9877</issn>
<issn pub-type="epub">1532-2777</issn>
<publisher><publisher-name>Elsevier Ltd.</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">32344313</article-id>
<article-id pub-id-type="pmc">7175844</article-id>
<article-id pub-id-type="publisher-id">S0306-9877(20)30618-6</article-id>
<article-id pub-id-type="doi">10.1016/j.mehy.2020.109776</article-id>
<article-id pub-id-type="publisher-id">109776</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Can pioglitazone be potentially useful therapeutically in treating patients with covid-19?</article-title>
</title-group>
<contrib-group><contrib contrib-type="author" id="au005"><name><surname>Carboni</surname>
<given-names>Elena</given-names>
</name>
<email>ecarboni@unica.it</email>
<xref rid="af015" ref-type="aff">c</xref>
<xref rid="cor1" ref-type="corresp">⁎</xref>
</contrib>
<contrib contrib-type="author" id="au010"><name><surname>Carta</surname>
<given-names>Anna Rosa</given-names>
</name>
<xref rid="af005" ref-type="aff">a</xref>
</contrib>
<contrib contrib-type="author" id="au015"><name><surname>Carboni</surname>
<given-names>Ezio</given-names>
</name>
<xref rid="af005" ref-type="aff">a</xref>
<xref rid="af010" ref-type="aff">b</xref>
</contrib>
<aff id="af005"><label>a</label>
Department of Biomedical Sciences, University of Cagliari, Italy</aff>
<aff id="af010"><label>b</label>
Department of Paediatrics, Magna Graecia University of Catanzaro, Italy</aff>
<aff id="af015"><label>c</label>
Ezio Carboni, Dept. of Bimedical Sciences, Cittadella Universitaria di Monserrato, Blocco A, S.P. Monserrato Sestu km 0,7, 09042 Monserrato. CA, Italy</aff>
</contrib-group>
<author-notes><corresp id="cor1"><label>⁎</label>
Corresponding author. <email>ecarboni@unica.it</email>
</corresp>
</author-notes>
<pub-date pub-type="pmc-release"><day>22</day>
<month>4</month>
<year>2020</year>
</pub-date>
<pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="epub"><day>22</day>
<month>4</month>
<year>2020</year>
</pub-date>
<elocation-id>109776</elocation-id>
<history><date date-type="received"><day>1</day>
<month>4</month>
<year>2020</year>
</date>
<date date-type="accepted"><day>21</day>
<month>4</month>
<year>2020</year>
</date>
</history>
<permissions><copyright-statement>© 2020 Elsevier Ltd. All rights reserved.</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder></copyright-holder>
<license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p>
</license>
</permissions>
<abstract id="ab005"><p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic disease (COVID-19) that has spread globally causing more than 30,000 deaths. Despite the immense and ongoing global effort, no efficacious drugs to fight this plague have been identified and patients admitted to the intensive care units (ICU), for respiratory distress, are managed mostly by means of supportive care based on oxygen maintenance. Several authors have reported that the prevalence of hypertension, diabetes, cardiovascular and cerebrovascular diseases comorbidities were indeed frequent among patients with COVID-19, which suggests that these conditions are likely to aggravate and complicate the prognosis. What the aforementioned diseases have in common is a latent chronic inflammatory state that may be associated with the alteration of laboratory parameters that are typical of the metabolic syndrome and insulin resistance. In severe COVID-19 patients laboratory markers of inflammation such as C-reactive protein, IL-6, D-dimer, serum ferritin and lactate dehydrogenase are elevated in many patients; assessed since the 4th-6th day of illness onset, such increases seem to be predictive of an adverse prognosis. Our hypothesis is that drugs belonging to the family of thiazolidinediones (TZD) such as pioglitazone or rosiglitazone, approved for treating the condition of insulin resistance and the accompanying inflammation, could ameliorate the prognosis of those COVID-19 patients with diabetes, hypertension and cardiovascular disorders comorbidities. TZD are PPARγ agonists that act on nuclear receptors, thereby triggering certain transcription factors. TZD were widely used for type-2 diabetes in the first decade of this century and although concerns have been raised for possible side effects associated with long-term treatment, their use has been recently revaluated for their anti-inflammatory properties in numerous medical conditions.</p>
</abstract>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000773 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000773 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= StressCovidV1 |flux= Pmc |étape= Curation |type= RBID |clé= PMC:7175844 |texte= Can pioglitazone be potentially useful therapeutically in treating patients with covid-19? }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:32344313" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \ | NlmPubMed2Wicri -a StressCovidV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |